1.New advances in molecular biology of prostate cancer
Journal of Medical and Pharmaceutical Information 2004;10():12-15
Prostate cancer is the most common detected cancer and the second cause of mortality in male patient aged > 45 in many countries in the world. New advances in molecular biology and genetics in association with great achievements in biological technology permit identily the creation and the process of prostate cancer in various profiles. The role of inflammation in the onset of prostate cancer is opened slightly. Research permits to predict new markers and to make promises for new treatments efficacy progressively against this dangerous disease of increasing concern
Prostatic Neoplasms
;
Molecular Biology
;
prostate
;
neoplasms
2.Pheochromocytoma of the bladder - Report of two new cases
Journal of Medical and Pharmaceutical Information 2004;0(9):37-39
Report of two cases of pheochromocytoma of the bladder to note its variable and misleading features. Pheochromocytoma of the bladder is a rare disease, that develops in the bladder from sympathetic plexus. This kind of tumor accounted for 10 to 15% of paragangliomas, 1% of pheochrocytomas and 0.1% of bladder tumors. This disease is more common at age 40 and in women than men (3/1). The diagnosis is based on biochemical tests and current imaging techniques, particularly ultrasonography and computerized tomography. Careful follow-up is mandatory because the tumors may progress to malignancy
Pheochromocytoma
;
Urinary Bladder
3.Cytomegalovirus in the kidney transplantation
Journal of Medical and Pharmaceutical Information 2002;12():10-13
Cytomegalovirus always is risk of complication and mortality for patients with kidney transplantation. The timely, effective diagnosis and treatment is a leading responsibility while waiting for vaccine responding with this virus. The diagnosis of cytomegalovirus based on the detection of pieces of cytomegalovirus in the cell, viral culture and serum test. ELISA is common method to detect the IgG and IgM. The treatment involved the use of anti-viral agents such as ganciclovir, foscarnet...
Kidney Transplantation
;
Cytomegalovirus
4.Results of extracorporeal lithotripsy by Storz Modulith SLX in Viet Duc hospital
Journal of Vietnamese Medicine 1998;230(11):1-4
From June 1996 to August 2000, we have prospectively followed 687 patients (476 renal stones, 224 ureteral stones) who underwent extracorporeal shock lithotripsy on a Storz-Modulith SLX in Viet Duc hospital. The member of stone - free cases in one session were achieved in 325 patients (46.4%). The effectiveness quotient, EQ was 62%. There were no severe complications, 12 patients underwent further operations and other thirty have had stone fragments to be removed by ureteroscopy. The success rates depend on following strick indications and improving performance on technical management on lithotriptor.
Lithotripsy
;
surgery
;
therapeutics
5.Results of resection of adrenal tumor by method with initial control of adrenal vessels before removing the tumor
Journal of Vietnamese Medicine 1999;233(2):143-151
Between 1/1994 and 12/2000, 52 patients with 53 adrenal tumors were operated in the Department of Urology - Viet Duc Hospital. Through subcostal approach, the initial control of the main adrenal veins and arteries was performed in 84.6% cases (71% in the right and 100% in the left adrenal tumors). Hemodynamic is maintained at the first day of postoperative period (88.5%). The outcome was good in 96.2% of cases, exception for one death at the third postoperative day by acute adrenal failure and another from prolonged hypertension. No early hemorrhage was observed in the postoperative period. Improved surgical outcomes have been the result of advances in localization techniques, preoperative medical management and anesthetic practice.
Neoplasms
;
surgery
;
therapeutics
6.Telomerase and urological cancer
Journal of Medical and Pharmaceutical Information 2001;(11):15-18
Currently, the telomerase is being considered as a marker of cancer because 90% of cancer cells in human have positive telomerase. The telomarase used to early diagnose, monitor and predict after the treatment. In addition to, telomerase also is objective of many researches to treat the cancer. It had better combine the anti telomerase and chemotherapy
Urologic Neoplasms
;
Telomerase
7.Telomerase and urological cancer
Journal of Preventive Medicine 2001;11(4):1-4
Telomerase is a ribonucleoprotein enzyme. Which is responsible for catalyst for increasing chains of telomere and limitation of shortening the chromosome terminal head. Telomerase has activity for the primary cells but inhibited differentiate cells. Telomerase was considered most significantly as a marker of cancer because 90% of cancer cells in human had positive telomerase. The telomerase was used to early diagnose and monitor as well as predict outcome. The antitelomerase therapy was a proper method to prevent relapsed cancer after the traditional treatments
Urologic Neoplasms
;
Telomerase
8.Apoptosis and urological disease
Journal of Medical and Pharmaceutical Information 1998;(1):14-17
Apoptosis is a 'programmed cell death' phenomenon that having the hereditary of nucleus cells. Apoptosis was described by Kerr in 1972 to introduced a popular phenomenon which is essential for the life, normal development of the body, the stability of tissue, elimination of inflammatory and tolerance of immunology
Urologic Diseases
;
Apoptosis
9.Results of treatment of benign prostate hypertrophy by endoscopic surgery during 1981 - 1996 in Viet Duc hospital
Journal of Vietnamese Medicine 1999;232(1):5-11
From 6/1981 to 6/1996 a total of 978 consecutive patients (mean age: 69) presenting with bladder outlet obstructive were admitted to Viet Duc hospital for elective transurethral resection of prostate). The feagure of TURP were increasing from year to year and the TURP/ open surgery ratio was 80% in 1996. The procedures were performed with low mortality (0.3%) and low morbidity (bleeding 0.6%, capsular perforation (0.7%). TURP syndrome (0.3%), dysuria (1.8%) incontinence (1.1%), urethral stricture (1.5%) Hospital stay: 5(2 days. Overall outcome: good: 77%, moderate 19%; unsatis factory: 4%.
Prostatic Hyperplasia
;
therapy
;
surgery
10.Genetic factors in prostate cancer and their clinical applications
Journal of Medical and Pharmaceutical Information 2003;0(3):19-21
Genetic factor is considered a special risk in prostate cancer. This article introduced some investigations of genes in prostate cancer. Genetic mechanisms in this disease may be complicated and diversified due to mutations or minor variations but major impact. It is shown current attitude of clinicians for hereditary prostate cancer
Prostatic Neoplasms
;
Prostate
;
Mutation
;
Genes